421 related articles for article (PubMed ID: 24574393)
21. The nucleoprotein of influenza A virus inhibits the innate immune response by inducing mitophagy.
Zhang B; Xu S; Liu M; Wei Y; Wang Q; Shen W; Lei CQ; Zhu Q
Autophagy; 2023 Jul; 19(7):1916-1933. PubMed ID: 36588386
[TBL] [Abstract][Full Text] [Related]
22. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
[TBL] [Abstract][Full Text] [Related]
23. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
[TBL] [Abstract][Full Text] [Related]
24. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P; Dispenzieri A; Galanis E
Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
[TBL] [Abstract][Full Text] [Related]
25. Measles virus suppresses RIG-I-like receptor activation in dendritic cells via DC-SIGN-mediated inhibition of PP1 phosphatases.
Mesman AW; Zijlstra-Willems EM; Kaptein TM; de Swart RL; Davis ME; Ludlow M; Duprex WP; Gack MU; Gringhuis SI; Geijtenbeek TB
Cell Host Microbe; 2014 Jul; 16(1):31-42. PubMed ID: 25011106
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
27. UBXN1 interferes with Rig-I-like receptor-mediated antiviral immune response by targeting MAVS.
Wang P; Yang L; Cheng G; Yang G; Xu Z; You F; Sun Q; Lin R; Fikrig E; Sutton RE
Cell Rep; 2013 Apr; 3(4):1057-70. PubMed ID: 23545497
[TBL] [Abstract][Full Text] [Related]
28. Potential and clinical translation of oncolytic measles viruses.
Robinson S; Galanis E
Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
[TBL] [Abstract][Full Text] [Related]
29. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
[TBL] [Abstract][Full Text] [Related]
30. Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.
Wang B; Yan X; Guo Q; Li Y; Zhang H; Xie JS; Meng X
Oncotarget; 2015 Jun; 6(18):16019-30. PubMed ID: 25909216
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
32. The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.
Dey A; Zhang Y; Castleton AZ; Bailey K; Beaton B; Patel B; Fielding AK
Mol Ther; 2016 Feb; 24(1):184-92. PubMed ID: 26278331
[TBL] [Abstract][Full Text] [Related]
33. Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy.
Wang R; Zhu Y; Ren C; Yang S; Tian S; Chen H; Jin M; Zhou H
Autophagy; 2021 Feb; 17(2):496-511. PubMed ID: 32013669
[TBL] [Abstract][Full Text] [Related]
34. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
35. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy of myeloma xenografts by an attenuated measles virus.
Peng KW; Ahmann GJ; Pham L; Greipp PR; Cattaneo R; Russell SJ
Blood; 2001 Oct; 98(7):2002-7. PubMed ID: 11567982
[TBL] [Abstract][Full Text] [Related]
37. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.
Lal S; Peng KW; Steele MB; Jenks N; Ma H; Kohanbash G; Phillips JJ; Raffel C
Hum Gene Ther Clin Dev; 2016 Dec; 27(4):145-151. PubMed ID: 27604429
[TBL] [Abstract][Full Text] [Related]
38. Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.
Rahman MM; Bagdassarian E; Ali MAM; McFadden G
Sci Rep; 2017 Nov; 7(1):15710. PubMed ID: 29146961
[TBL] [Abstract][Full Text] [Related]
39. A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.
Kurokawa C; Iankov ID; Galanis E
Virus Res; 2019 Apr; 263():145-150. PubMed ID: 30684519
[TBL] [Abstract][Full Text] [Related]
40. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
